期刊
JOURNAL OF NEUROBIOLOGY
卷 61, 期 1, 页码 149-160出版社
WILEY
DOI: 10.1002/neu.20080
关键词
cannabinoid; endocannabinoid; pain; fatty acid amide hydrolase; CB1 receptor; CB2 receptor; agonist; antagonist; inhibitor
资金
- NIDA NIH HHS [R01 DA015197-02, DA015197, DA03672, R01 DA015197, P01 DA017259, DA017259, P01 DA017259-01, DA09789] Funding Source: Medline
The analgesic properties of exogenous cannabinoids have been recognized for many years and suggest a regulatory role for the endogenous cannabinoid (endocannabinoid) system in mammalian nociceptive pathways. The endocannabinoid system includes: (1) at least two families of lipid signaling molecules, the N-acyl ethanolamines (e.g., anandamide) and the monoacylglycerols (e.g., 2-arachidonoyl glycerol); (2) multiple enzymes involved in the biosynthesis and degradation of these lipids, including the integral membrane enzyme fatty acid amide hydrolase; and (3) two G-protein coupled receptors, CB1 and CB2, which are primarily localized to the nervous system and immune system, respectively. Here, we review recent genetic, behavioral, and pharmacological studies that have tested the function of the endocannabinoid system in pain sensation. Collectively, these investigations support a role for endocannabinoids in modulating behavioral responses to acute, inflammatory, and neuropathic pain stimuli. (C) 2004 Wiley Periodicals, Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据